Previously writing on company which describes itself as “a leading medical device company in the field of regenerative medicine” Tissue Regenix (TRX), in January I questioned “robust financial and operational performance”. So what of now results for the first half of 2022?
Describing itself as “a leading medical devices company in the field of regenerative medicine” Tissue Regenix (TRX) has made a full-year trading update headlined “Return to double digit growth in 2021” and concluding “the company has delivered robust financial and operational performance”. Why then are the shares still below 0.50p, compared to above 1.2p in May 2020?...
Tissue Regenix (TRX) has announced results for the first half of 2021 claiming “we have created a commercially focussed regenerative global medtech company in a high growth sector… encouraged by our strong H1 results” and that we “look forward to this being further built on in H2”. So why are the shares, at 0.675p, currently more than 4% lower?
I first warned on shares in Tissue Regenix (TRX) in October as they fell below 3p and most recently above 1p earlier this month, noting still a required fundraising ahoy. Today an announcement; “Confirmation of successful fundraising”...
An announcement from ‘regenerative medicine medical devices company’ Tissue Regenix (TRX) – and the shares currently above 1p, more than 55% higher. Though “New collaboration with leading healthcare company” ramptastic?...
‘Regenerative medicine’ medical devices company Tissue Regenix (TRX) has updated including that currently “the San Antonio facility remains fully operational” and the company “has not experienced any material reduction in net revenues versus expectations”. However, the shares have currently responded to below 0.40p, circa 35% lower…
Shares in ‘regenerative medical devices’ group Tissue Regenix (TRX) are currently approaching 20% higher on the day, at around 1.20p, on the back of an update including “it is anticipated that delayed orders will be dispatched over the coming weeks… All processing in the company's United States facility has also resumed with immediate effect”…
An announcement from Tissue Regenix (TRX), a Woodford pick (uh oh), at an intra-day 10:02am (uh oh); “Notice of cyber security incident”. Oh dear! – and particularly considering the company’s previous announcement included that it only “believes that the available cash runway will continue to support the working capital requirement of the company until the end of April 2020”!...
A “Trading Update” from Woodford stock Tissue Regenix (TRX) – and the shares currently around 1.40p, down (natch!) approaching 20%...
